ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO30

Cure Glomerulonephropathy (CureGN) Network

Session Information

Category: Glomerular Diseases

  • No subcategory defined

Authors

  • Canetta, Pietro A., Columbia University Irving Medical Center, New York, New York, United States
  • Palmer, Matthew, Penn Medicine, Philadelphia, Pennsylvania, United States
  • Royal, Virginie, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Sedor, John R., Cleveland Clinic, Cleveland, Ohio, United States
  • Gbadegesin, Rasheed A., Duke University Health System, Durham, North Carolina, United States
  • Poulton, Caroline J., University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Wenderfer, Scott E., Texas Children's Hospital, Houston, Texas, United States
  • Hladunewich, Michelle A., Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  • Mottl, Amy K., University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Bomback, Andrew S., Columbia University Irving Medical Center, New York, New York, United States
  • Klein, Jon B., University of Louisville School of Medicine, Louisville, Kentucky, United States
  • Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
  • Rizk, Dana, The University of Alabama at Birmingham, Birmingham, Alabama, United States

Group or Team Name

  • CureGN Consortium
Description

CureGN is a multi-center, prospective observational cohort study of glomerular disease funded by the NIH-NIDDK. CureGN has enrolled 2,410 participants with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy from 66 sites internationally since Dec. 2014.

Patients biopsied within 5 years are eligible to participate. Exclusion criteria include ESKD at enrollment, diabetes at biopsy, and glomerular disease attributed to a secondary cause. Sociodemographic, clinical, pathologic, and patient reported data collection is enriched by a diverse biorepository and digital pathology repository (DPR). Renal and non-renal outcomes are collected. Participant characteristics with median 2.7 year follow up are shown (Table).

CureGN supports multi-dimensional translational research by combining clinical phenotype, pathology, and outcome data with longitudinally collected DNA, RNA, blood, urine specimens. The DPR can provide annotated images or quantitative scoring data from kidney biopsies for investigators. An online data-sharing tool (tranSMART) is available for hypothesis generation.

The study objectives support a variety of ways to identify mechanistically distinct subgroups, discover/validate biomarkers, delineate disease-specific treatment targets, and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular diseases. Patient input into the study is integrated via a patient advisory panel. The Career Development Group provides peer mentoring for young investigators interested in glomerular disease. The consortium is open to ancillary study proposals from Network and extramural investigators.

Funding

  • This work was supported by the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIH NIDDK) [grant numbers: UM1DK100845, UM1DK100846, UM1DK100876, UM1DK100866, and UM1DK100867]. Dates of funding for CureGN-1 are 9/16/2013-5/31/2019, and for CureGN-2 are 6/1/2020 - 5/31/2024.